U.S., April 4 -- ClinicalTrials.gov registry received information related to the study (NCT06908070) titled 'Chemoradiotherapy With Surgery Followed by Consolidation Durvalumab' on March 27.
Brief Summary: Lung cancer presents a significant treatment challenge, particularly in the heterogeneous stage III NSCLC patient population. While chemotherapy combined with high-dose radiotherapy (60 Gy in 30 fractions of 2 Gy once daily) is currently the recommended approach for unresectable stage III cases, it is associated with significant rates of locoregional and distant failures. Notably, the introduction of durvalumab consolidation therapy after chemoradiotherapy (CRT), as demonstrated in the PACIFIC study, has shown improved overall survival, ...